Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galunisertib and Capecitabine in Advanced Colorectal Cancer With Peritoneal Metastases
NCT05700656Phase 2Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jul 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of galunisertib in colorectal cancer (CRC), sponsored by Netherlands Cancer Institute. Started Jul 2023; status: active, not recruiting.
02
Drugs
galunisertib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05700656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05700656.